BR112017018160A2 - uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos - Google Patents

uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos

Info

Publication number
BR112017018160A2
BR112017018160A2 BR112017018160-6A BR112017018160A BR112017018160A2 BR 112017018160 A2 BR112017018160 A2 BR 112017018160A2 BR 112017018160 A BR112017018160 A BR 112017018160A BR 112017018160 A2 BR112017018160 A2 BR 112017018160A2
Authority
BR
Brazil
Prior art keywords
mva
combination
blocking agents
immune checkpoint
monoimmunotherapy
Prior art date
Application number
BR112017018160-6A
Other languages
English (en)
Inventor
Deng Liang
Shuman Stewart
D. Wolchok Jedd
Merghoub Taha
Dai Peihong
Wang Weiyi
Original Assignee
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan-Kettering Cancer Center filed Critical Memorial Sloan-Kettering Cancer Center
Publication of BR112017018160A2 publication Critical patent/BR112017018160A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente divulgação refere-se a vaccinia ankara modificado (mva) inativado competente em relação à infecção, mas não replicativo e seu uso como imunoterpia, sozinho ou em combinação com agentes de bloqueio de pontos de verificação imunológica para o tratamento de tumores sólidos malignos. modalidades particulares referem-se à indução de uma resposta imunológica em um indivíduo diagnosticado com um tumor maligno sólido.
BR112017018160-6A 2015-02-25 2016-02-25 uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos BR112017018160A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120862P 2015-02-25 2015-02-25
US62/120,862 2015-02-25
PCT/US2016/019663 WO2016144564A2 (en) 2015-02-25 2016-02-25 Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors

Publications (1)

Publication Number Publication Date
BR112017018160A2 true BR112017018160A2 (pt) 2018-04-10

Family

ID=56879727

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018160-6A BR112017018160A2 (pt) 2015-02-25 2016-02-25 uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos

Country Status (10)

Country Link
US (2) US10639366B2 (pt)
EP (2) EP3261669B1 (pt)
JP (1) JP2018510143A (pt)
KR (1) KR20170138996A (pt)
CN (2) CN115300622A (pt)
AU (1) AU2016229408A1 (pt)
BR (1) BR112017018160A2 (pt)
CA (1) CA2977660A1 (pt)
HK (1) HK1251459A1 (pt)
WO (1) WO2016144564A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
US20200085891A1 (en) * 2017-04-21 2020-03-19 Sillajen, Inc Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CA3081347A1 (en) * 2017-11-06 2019-05-09 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
KR20200131863A (ko) * 2018-03-13 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스
US20210085736A1 (en) * 2018-04-20 2021-03-25 The University Of Hong Kong Immuno-oncolytic modified vaccinia tian tan virus and methods of treating cancer
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
AU2019336940A1 (en) * 2018-09-06 2021-03-11 Bavarian Nordic A/S Storage improved poxvirus compositions
WO2021232019A1 (en) * 2020-05-15 2021-11-18 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with immune checkpoint inhibitors
CN116507360A (zh) * 2020-08-17 2023-07-28 北欧科学集团组有限责任公司 用于通过改变肿瘤微环境来治疗胃肠腺癌的组合物

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
ES2154738T3 (es) 1994-10-03 2001-04-16 Us Gov Health & Human Serv Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2000073487A1 (en) 1999-05-27 2000-12-07 Arizona Board Of Regents Novel viral vectors having enhanced effectiveness with dramatically reduced virulence
CA2375189C (en) 1999-05-28 2010-02-09 The Government Of The United States Of America A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
EP1227828A1 (en) 1999-11-12 2002-08-07 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
WO2001068820A1 (en) * 2000-03-14 2001-09-20 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
JP2004513184A (ja) 2000-11-20 2004-04-30 オンコリティクス　バイオテック，　インコーポレイティッド 固形腫瘍塊への最適なウイルス送達法
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US6750043B2 (en) 2001-04-19 2004-06-15 Arizona Board Of Regents Viral vectors having reduced virulence
US6372455B1 (en) 2001-04-19 2002-04-16 Arizona Board Of Regents Recombinant vaccinia viral vectors
US20040091995A1 (en) 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
US20030113919A1 (en) 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
DE10144664B4 (de) 2001-09-11 2005-06-09 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
US7001718B2 (en) 2001-12-20 2006-02-21 Massachusetts Institute Of Technology Method of inhibiting pathogenicity of infectious agents
US20070178065A1 (en) 2002-05-03 2007-08-02 Lattime Edmund C Neutralizing factors as vaccine adjuvants
DE10221411B4 (de) 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
EA007811B1 (ru) 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
WO2004042001A2 (en) 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
JP2004031674A (ja) 2002-06-26 2004-01-29 Disco Abrasive Syst Ltd コンタミネーション除去装置
WO2004009763A2 (en) 2002-07-24 2004-01-29 Arizona Board Of Regents Use of vaccinia virus deleted for the e3l gene as a vaccine vector
AU2003267361A1 (en) 2002-09-12 2004-04-30 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Orthopoxvirus antigens and use thereof
CA2511625A1 (en) 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
WO2004087047A2 (en) 2003-02-07 2004-10-14 Arizona Board Of Regents Mutants of replication competent vaccinia virus
DE602004018927D1 (de) 2003-06-18 2009-02-26 Genelux Corp Modifizierte rekombinante vacciniaviren, verwendungen davon
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
CA2436196A1 (en) 2003-07-25 2005-01-25 Oncolytics Biotech Inc. Oncolytic virus for purging cellular compositions of cells of lymphoid malignancies
CA2435967A1 (en) 2003-07-25 2005-01-25 Oncolytics Biotech, Inc. Reovirus for the treatment of lymphoid malignancies
US20070275010A1 (en) 2003-09-18 2007-11-29 Mark Feinberg Mva Vaccines
EP1518932A1 (en) 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
WO2006020949A2 (en) 2004-08-12 2006-02-23 Cedars-Sinai Medical Center Combined gene therapy for the treatment of macroscopic gliomas
EP1683870A1 (en) 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
EP1890724A2 (en) 2005-05-13 2008-02-27 Oxxon Therapeutics Limited Compositions for inducing an immune response
ES2281252B1 (es) 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20070077231A1 (en) 2005-09-30 2007-04-05 Contag Christopher H Immune effector cells pre-infected with oncolytic virus
WO2007100607A2 (en) 2006-02-24 2007-09-07 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides and methods of use
KR100788930B1 (ko) 2006-04-18 2007-12-27 포항공과대학교 산학협력단 항암 조성물
CA2665068C (en) 2006-10-06 2016-01-05 Bn Immunotherapeutics Inc. Methods for treating cancer with mva
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US20100316609A1 (en) 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
EP2173368A1 (en) 2007-07-18 2010-04-14 Genelux Corporation Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
EP2207564B1 (en) 2007-10-18 2016-10-05 Bavarian Nordic A/S Use of mva to treat prostate cancer
WO2009052617A1 (en) 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
NZ584199A (en) 2007-11-19 2012-07-27 Transgene Sa Poxviral oncolytic vectors comprising a defective 14l and/or f4l gene
MX2010005273A (es) 2007-11-19 2010-08-31 Transgene Sa Vectores oncoliticos poxvirales.
WO2009139921A2 (en) 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009152179A1 (en) 2008-06-09 2009-12-17 Arizona Board Of Regents Compositions, methods, and kits for eliciting an immune response
WO2010020056A1 (en) 2008-08-21 2010-02-25 Ottawa Hospital Research Institute Engineered synergistic oncolytic viral symbiosis
EP2424999A1 (en) 2009-04-30 2012-03-07 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Modified immunization vectors
CA2709292A1 (en) 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
WO2011156470A1 (en) 2010-06-08 2011-12-15 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University A method for inserting genetic material into genomic dna
WO2012009644A2 (en) 2010-07-16 2012-01-19 Arizona Board Of Regents Methods to identify synthetic and natural rna elements that enhance protein translation
CN103200962A (zh) 2010-09-23 2013-07-10 巴克斯特国际公司 重组病毒载体及用于诱导对黄热病毒的免疫反应的方法
CN103429258B (zh) 2011-01-04 2016-03-09 新罗杰公司 通过施用溶瘤痘苗病毒生成针对肿瘤抗原的抗体和生成肿瘤特异性补体依赖性细胞毒性
JP6415977B2 (ja) 2011-04-15 2018-10-31 ジェネラックス・コーポレイションＧｅｎｅｌｕｘ Ｃｏｒｐｏｒａｔｉｏｎ 弱毒化ワクシニアウイルスのクローン株およびその使用方法
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
EP2771465A1 (en) 2011-10-28 2014-09-03 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Genetic element that enhances protein translation
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
US20140086976A1 (en) 2012-08-20 2014-03-27 Aladar A. Szalay Compositions containing protein polymers and vaccinia virus, and methods of use thereof
CN104704002B (zh) 2012-08-30 2022-05-10 安姆根有限公司 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
WO2014037124A1 (en) 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014047350A1 (en) 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
US20180200320A1 (en) 2012-11-21 2018-07-19 Aviratek Biomedical Solutions, Llc Method and compositions for the use of botanical extracts in the treatment of viral infections, cancer, pain, itch, and inflammation
US20140193859A1 (en) 2013-01-08 2014-07-10 Bertram Jacobs Temperature-dependent insertion of genetic material into genomic DNA
US20140271549A1 (en) 2013-03-15 2014-09-18 Aladar A. Szalay Use of Antibiotics to Enhance Treatment With Therapeutic Viruses
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
GB201310917D0 (en) 2013-06-19 2013-07-31 Cancer Res Inst Royal Vaccinia virus for gene-directed enzyme prodrug therapy
WO2015027163A1 (en) 2013-08-22 2015-02-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Immuno-oncolytic therapies
WO2015066715A1 (en) 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
JP6535337B2 (ja) 2013-11-05 2019-06-26 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
RU2744194C2 (ru) 2013-12-02 2021-03-03 Фио Фармасьютикалс Корп Иммунотерапия рака
CA2934073A1 (en) 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US20170106065A1 (en) 2013-12-31 2017-04-20 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
WO2015138471A1 (en) 2014-03-10 2015-09-17 Arizona Board Of Regents On Behalf Of Arizona State University Heat inactivated poxvirus improves vaccination results
WO2015138741A1 (en) 2014-03-12 2015-09-17 Cars-N-Kids Llc Systems and methods for determining if a child safety seat is in a moving vehicle
GB201405834D0 (en) 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
AU2015259510B2 (en) 2014-05-13 2020-10-01 Bavarian Nordic A/S Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
JP6843736B2 (ja) 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
MX2017002791A (es) * 2014-09-03 2017-05-30 Bavarian Nordic As Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
JP2017530114A (ja) 2014-09-26 2017-10-12 バヴァリアン・ノルディック・アクティーゼルスカブ フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
EP3256156A1 (en) 2015-02-13 2017-12-20 Transgene SA Immunotherapeutic vaccine and antibody combination therapy
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
ES2795010T3 (es) 2015-06-19 2020-11-20 Sillajen Inc Composiciones y métodos para la embolización viral
CN105039269A (zh) 2015-07-24 2015-11-11 北京鼎成肽源生物技术有限公司 一种用于治疗非小细胞肺癌的新型病毒疫苗及其制备方法
AU2016302237B2 (en) 2015-08-03 2022-08-04 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
EP3347460A4 (en) 2015-09-08 2019-04-10 Sillajen, Inc. MODIFIED ONCOLYTIC VACCINE VIRUSES EXPRESSING CYTOKINE AND CARBOXYESTERASE AND METHODS OF USE THEREOF
EP3347473A4 (en) 2015-09-09 2019-04-10 Tvax Biomedical I, LLC METHODS FOR COMBINING ADOPTIVE TRANSFER THERAPY OF T-CELLS WITH ONCOLYTIC VIRUS ADHERENCE THERAPY
JP7171433B2 (ja) 2015-10-30 2022-11-15 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
EP3426271A4 (en) 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
WO2017205674A1 (en) 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
AU2017298385A1 (en) 2016-07-19 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting STAT3
US11452770B2 (en) 2016-07-21 2022-09-27 Kolon Life Science, Inc. Recombinant vaccinia virus and use thereof
KR20230113832A (ko) 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
EP3515419A4 (en) 2016-09-21 2020-06-10 Stephen H. Thorne HIGH MOBILITY GROUP 1 BOX MUTANT
US20200046784A1 (en) 2016-09-30 2020-02-13 University Health Network Recombinant oncolytic viruses for cancer therapy
SG11202102439WA (en) 2018-09-15 2021-04-29 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy

Also Published As

Publication number Publication date
CN107735103B (zh) 2022-05-27
EP3261669A2 (en) 2018-01-03
AU2016229408A1 (en) 2017-09-14
HK1251459A1 (zh) 2019-02-01
WO2016144564A2 (en) 2016-09-15
US11426460B2 (en) 2022-08-30
US20200237902A1 (en) 2020-07-30
US20180236062A1 (en) 2018-08-23
CN115300622A (zh) 2022-11-08
KR20170138996A (ko) 2017-12-18
CA2977660A1 (en) 2016-09-15
EP4122492A1 (en) 2023-01-25
EP3261669A4 (en) 2018-07-25
JP2018510143A (ja) 2018-04-12
EP3261669B1 (en) 2022-08-03
WO2016144564A9 (en) 2016-11-03
CN107735103A (zh) 2018-02-23
US10639366B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
BR112017018160A2 (pt) uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos
CO2018013738A2 (es) Novedosos virus vaccinia modificados genéticamente
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
BR112016008806A2 (pt) Vetores para expressão de antígenos associados à próstata
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112017020149A8 (pt) Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
BR112016028066A2 (pt) composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira
UY35965A (es) Anticuerpos humanos contra pd?l1
UY35964A (es) Anticuerpos humanos para pd?1
BR112019005305A2 (pt) compostos espirocíclicos
BR112018016948A2 (pt) mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
BR112019002646A2 (pt) composições de poxvírus quimérico e usos das mesmas
BR112017023579A2 (pt) combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018016949A2 (pt) vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer
CA3060516A1 (en) Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
EA201800148A1 (ru) Оспенная вакцина для лечения рака
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201691314A1 (ru) Терапевтические способы и композиции

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements